Anti-ANGPTL3 antibodies suitable for high concentration compositions and subcutaneous administration
US11780910B1 · kind B1 · utility
0Cited by
6References
24Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 2, 2023 |
| Grant date | Oct 10, 2023 |
| Priority date | — |
| Expiry date | May 2, 2043 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to novel monovalent anti-ANGPTL3 antibodies for use in medicine and in particular for lowering of plasma triglycerides levels in patients in need thereof, such as patients suffering from or at risk of hypertriglyceridemia and/or cardiovascular disease, such as atherosclerotic cardiovascular disease (ASCVD) as well as pharmaceutical compositions suitable for subcutaneous administration and kits comprising such compounds and compositions.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.